Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 23, 2026 22:47 UTC |
Levine James E.Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $13.86 | $0.00 |
DisclosureSEC source: 0001213900-26-071231 · ownership.xml · derivative · entry 1 Levine James E. · CIK 0001463151 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: ADSs · 200,000 shares Expires not disclosed F1 · shares: Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. F1 · derivative.exercise_date: Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. F1 · derivative.expiration_date: Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 22:47 UTC |
Rao SudhaChief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001213900-26-071230 · ownership.xml · derivative · entry 1 Rao Sudha · CIK 0002132027 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: ADSs · 250,000 shares Expires not disclosed F1 · shares: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. F1 · derivative.exercise_date: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. F1 · derivative.expiration_date: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:59 UTC |
Coffey Steven R. S.Director
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001213900-26-076431 · ownership.xml · derivative · entry 1 Coffey Steven R. S. · CIK 0002121676 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: ADSs · 100,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:59 UTC |
Friend John E. IIChief Executive Officer
|
GrantRestricted Share Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-076430 · ownership.xml · derivative · entry 2 Friend John E. II · CIK 0001704021 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: ADSs · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. F2 · derivative.exercise_date: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. F2 · derivative.expiration_date: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:59 UTC |
Friend John E. IIChief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001213900-26-076430 · ownership.xml · derivative · entry 1 Friend John E. II · CIK 0001704021 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: ADSs · 500,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:58 UTC |
Bonacorda JeffreyVP, Finance and Controller
|
GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001213900-26-076429 · ownership.xml · derivative · entry 1 Bonacorda Jeffrey · CIK 0002115111 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: ADSs · 150,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:58 UTC |
Davidson EbruDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001213900-26-076428 · ownership.xml · derivative · entry 1 Davidson Ebru · CIK 0002135805 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: ADSs · 100,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:57 UTC |
APPLE ROBERT FDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001213900-26-076426 · ownership.xml · derivative · entry 1 APPLE ROBERT F · CIK 0001054942 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: ADSs · 75,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
| January 08, 2026 Filed Jul 8, 2026 20:57 UTC |
Cain DavidDirector, CMC
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001213900-26-076427 · ownership.xml · derivative · entry 1 Cain David · CIK 0002125950 · Director, CMC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: ADSs · 100,000 shares Expires not disclosed F1 · shares: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.exercise_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. F1 · derivative.expiration_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.